PDCD1 and neoplasm: Gopalakrishnan et al. investigate the oral and intestinal microbiota of 112 patients receiving anti-PD-1 immunotherapies, where 30 “responsive” patients contain a higher abundance of Ruminococcaceae family bacteria in their feces and a more abundant synthetic metabolic pathway in their bodies, resulting in stronger systemic immunity and anti-tumor immunity [131].